CUP0 Stock Overview
Engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for CUP0 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Chugai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥19.50 |
| 52 Week High | JP¥22.60 |
| 52 Week Low | JP¥18.00 |
| Beta | 0.50 |
| 1 Month Change | 2.63% |
| 3 Month Change | -8.88% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 7.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| CUP0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -0.3% | -0.2% |
| 1Y | n/a | -17.0% | 7.0% |
Return vs Industry: Insufficient data to determine how CUP0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CUP0 performed against the German Market.
Price Volatility
| CUP0 volatility | |
|---|---|
| CUP0 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CUP0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine CUP0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 7,604 | Osamu Okuda | www.chugai-pharm.co.jp |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group.
Chugai Pharmaceutical Co., Ltd. Fundamentals Summary
| CUP0 fundamental statistics | |
|---|---|
| Market cap | €69.59b |
| Earnings (TTM) | €2.36b |
| Revenue (TTM) | €6.96b |
30.2x
P/E Ratio10.2x
P/S RatioIs CUP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUP0 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.14t |
| Cost of Revenue | JP¥337.17b |
| Gross Profit | JP¥805.18b |
| Other Expenses | JP¥418.22b |
| Earnings | JP¥386.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 235.16 |
| Gross Margin | 70.48% |
| Net Profit Margin | 33.87% |
| Debt/Equity Ratio | 0% |
How did CUP0 perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield34%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 20:50 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chugai Pharmaceutical Co., Ltd. is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Siti Bte Salikin | CFRA Equity Research |